Advances in therapeutic options for newly diagnosed, high-risk AML patients. (May 2021)

• Record Type: Journal Article
• Authors: Doucette, Kimberley; Karp, Judith; Lai, Catherine
• Is Part Of: Therapeutic advances in hematology. Volume 12(2021)
• Publication Date: 2021-05
• Subjects: acute myeloid leukemia -- adverse risk -- high risk -- newly diagnosed -- therapy; Hematology -- Periodicals; Hematologic Diseases -- therapy -- Periodicals; Hematology -- Periodicals; 616.15005
• DOI: 10.1177/20406207211001138
• Languages: English
• ISSNs: 2040-6207

Abstract

Acute myeloid leukemia (AML) is an aggressive malignancy characterized by clonal proliferation of neoplastic immature precursor cells. AML impacts older adults and has a poor prognosis. Despite recent advances in treatment, AML is complex, with both genetic and epigenetic aberrations in the malignant clone and elaborate interactions with its microenvironment. We are now able to stratify patients on the basis of specific clinical and molecular features in order to optimize individual treatment strategies. However, our understanding of the complex nature of these molecular abnormalities continues to expand the defining characteristics of high-risk mutations. In this review, we focus on genetic and microenvironmental factors in adverse risk AML that play critical roles in leukemogenesis, including those not described in an European LeukemiaNet adverse risk group, and describe therapies that are currently in the clinical arena, either approved or under development.